The latest COVID flu rsv vaccine recommendations are taking shape for the 2026-2027 respiratory virus season, with updated formulations, revised eligibility details and important timing guidance now in place for Americans.
The fall vaccination landscape looks different from previous years. Flu vaccination continues to cover people 6 months and older, while RSV vaccination remains targeted toward specific age groups and people at higher risk. COVID vaccination now follows an individual-based approach, with the benefits depending more heavily on age, health status and personal risk.
At the same time, federal health officials have updated the products available for the coming season. The new COVID formula targets the JN.1-lineage XFG variant, while all three components of the 2026-2027 flu vaccine have been updated. RSV guidance continues to emphasize vaccination before seasonal circulation increases.
For Americans planning fall health appointments, understanding the differences between these three vaccines can make the process much easier.
What is changing for the 2026-2027 season?
The biggest development this fall is that all three respiratory illnesses have distinct vaccination policies.
The 2026-2027 flu vaccine contains updated virus components designed to match influenza viruses expected to circulate during the new season. Federal officials updated all three components compared with the previous year’s vaccine.
The COVID vaccine has also received a new seasonal formulation. The Food and Drug Administration selected a monovalent vaccine based on the JN.1-lineage XFG variant for use beginning in fall 2026.
RSV vaccination remains more selective. Adults do not automatically need a new RSV dose every year. Current guidance calls for a single dose for eligible adults, with no additional dose recommended at this time after someone has already received one.
That difference is important. A person may need a flu vaccine this fall even after receiving one last year, while the same person may not need another RSV dose.
Flu vaccination remains an annual priority
Flu continues to have the broadest vaccination recommendation of the three.
The current guidance covers everyone 6 months and older who does not have a medical reason to avoid vaccination. That includes children, working-age adults, older adults and pregnant people.
The 2026-2027 vaccine is trivalent. It contains protection against three influenza virus components.
All three components have been updated for the new season. One significant change addresses an H3N2 subclade that circulated widely during the previous flu season.
This annual update is necessary because influenza viruses change over time. Vaccine manufacturers and public health officials review circulating viruses and update the vaccine composition for the upcoming season.
For most Americans, September and October remain the preferred months for vaccination. Getting vaccinated during this period can provide protection as influenza activity begins to increase later in the year.
However, people should not assume that missing September or October means they should skip vaccination. Flu viruses can circulate well into the winter and spring, so vaccination can still provide value while influenza remains active.
Why the new flu formula matters
The 2026-2027 flu vaccine is not simply a repeat of last year’s product.
Federal regulators recommended changes to all three vaccine components. The updates include changes involving both H1N1 and H3N2 influenza A viruses, as well as the B/Victoria lineage.
The changes reflect ongoing surveillance of influenza viruses in the United States and internationally.
The H3N2 update is particularly notable because a specific H3N2 subclade spread widely during the 2025-2026 season. Updating the vaccine allows manufacturers to produce a formulation better aligned with the viruses expected to circulate.
For consumers, the practical message is straightforward: the new season’s flu vaccine is designed specifically for the 2026-2027 season.
Flu vaccine timing for children
Children require special attention because some children need two doses during a vaccination season.
Children who require two doses need enough time between those doses to complete the recommended series. Parents should therefore avoid waiting until influenza activity is already widespread.
The number of doses depends on the child’s age and previous vaccination history.
Parents should also make sure the vaccination record is available when discussing the upcoming flu shot with a pediatric healthcare professional. Previous doses can affect the schedule.
Children younger than 6 months are not eligible for flu vaccination. Protection for very young infants instead depends heavily on vaccination of eligible household members and vaccination during pregnancy.
What is new about the COVID vaccine?
The COVID vaccination landscape has changed considerably.
For the 2026-2027 season, the updated formula targets the JN.1-lineage XFG variant. Federal regulators selected this formulation after reviewing information about circulating variants, vaccine effectiveness, immune responses and other available evidence.
The updated formulation is intended to more closely match currently circulating viruses.
Several FDA-approved COVID vaccines are available in the United States, but eligibility can differ by product and age.
The current federal approach uses individual-based decision-making. This means the decision is made by considering factors such as age, health status, risk of severe disease and vaccination history rather than applying one identical recommendation to everyone.
That makes personal circumstances particularly important this fall.
Who should pay close attention to COVID vaccination?
Older adults deserve particular attention because age remains a major risk factor for severe COVID illness.
People with conditions that increase the risk of severe disease also have an important reason to discuss vaccination with a healthcare professional.
The same applies to people with weakened immune systems. Current guidance specifically addresses people who are moderately or severely immunocompromised and provides modified vaccination schedules based on age and previous vaccination.
People in these groups should not assume that the general schedule applies to them.
Their vaccination history can affect how many doses they need and the appropriate interval between doses.
The updated 2026-2027 vaccine is therefore particularly relevant for people deciding whether they are due for seasonal protection.
COVID vaccination after a recent infection
A recent COVID infection can affect the timing of vaccination.
Current guidance allows people who recently had COVID to consider delaying vaccination for about three months after symptom onset or a positive test when they had no symptoms.
However, the timing can depend on individual circumstances.
Someone at high risk for severe disease, someone living with a high-risk household member or someone facing increased local transmission may have reasons to vaccinate sooner.
This is another reason the current system relies on individual decision-making rather than a single schedule for everyone.
RSV vaccination follows a different pattern
RSV vaccination is much more targeted than flu vaccination.
Current recommendations call for all adults 75 and older to receive an RSV vaccine.
Adults ages 50 through 74 may also qualify if they have an increased risk of severe RSV disease.
Risk factors can include certain chronic heart or lung conditions, weakened immunity, severe obesity, chronic liver disease, certain blood disorders and residence in a nursing home.
Frailty and other circumstances can also influence the assessment.
For adults in the 50-to-74 age range, the presence of a risk factor is central to determining whether vaccination is recommended.
RSV vaccination is not an annual shot
One of the most important points for consumers is that the RSV vaccine is currently not an annual vaccine.
Someone who received an RSV vaccine previously generally does not need another dose this year.
Current guidance recommends a single dose for eligible adults. Additional doses are not currently recommended.
This differs sharply from influenza vaccination.
A person who received an RSV vaccine last year may therefore not need another one during the 2026-2027 season, while that same person should still review their need for the new seasonal flu vaccine.
Federal health officials continue to evaluate how long RSV vaccine protection lasts and whether additional doses may become appropriate in the future.
When should adults get an RSV vaccine?
Eligible adults can receive an RSV vaccine at any time of year.
However, late summer and early fall are considered the preferred period in most of the continental United States.
The goal is to provide protection before RSV begins spreading more widely in communities.
August through October is generally the preferred window.
That timing makes September particularly important for people who qualify but have not yet received their first RSV dose.
Adults who already received an RSV vaccine should not simply schedule another dose because a new respiratory virus season has started.
Which RSV vaccines are available?
Three RSV vaccines are currently licensed for adults:
- Arexvy
- mResvia
- Abrysvo
Current guidance does not give one of these vaccines a general preference over the others for eligible adults.
The appropriate product can depend on age, indication, availability and the circumstances of the person receiving it.
People should also remember that RSV vaccination for adults is separate from strategies used to protect infants.
RSV protection during pregnancy
Pregnancy adds another important dimension to RSV prevention.
One RSV vaccine, Abrysvo, is used during pregnancy to help protect newborns against severe RSV illness.
The recommended window is during weeks 32 through 36 of pregnancy during the seasonal period when RSV protection is needed.
Maternal vaccination allows antibodies to pass to the developing baby before birth.
The strategy is especially important because very young infants can face a higher risk of severe RSV illness.
Pregnant people should discuss the appropriate timing with their healthcare professional rather than treating maternal RSV vaccination as the same recommendation used for older adults.
Protecting infants from RSV
Infant RSV prevention does not rely solely on maternal vaccination.
When an infant enters the first RSV season without adequate protection from maternal vaccination, an RSV antibody may be recommended.
Nirsevimab and clesrovimab are used for infant RSV prevention under current recommendations.
These products are antibodies rather than traditional vaccines.
The appropriate approach depends on factors such as maternal vaccination and the baby’s age and circumstances.
Parents should discuss RSV prevention before or during the infant’s first RSV season to determine which strategy applies.
Can the vaccines be given during the same visit?
Americans may be able to receive multiple recommended vaccines during one healthcare visit.
Flu and COVID vaccination can be administered at the same visit. There is no required waiting period between these two vaccines.
RSV vaccination can also be given during the same visit as other adult vaccines when the person is eligible.
Receiving several vaccines during one appointment can make seasonal vaccination more convenient.
It does not mean that everyone needs all three vaccines.
Eligibility remains the key consideration.
An older adult could qualify for all three, while a younger healthy adult might have a different vaccination plan.
Current respiratory virus activity heading into fall
The latest national surveillance available before September 3 shows a relatively low level of overall acute respiratory illness.
COVID activity has been increasing nationally and in several regions.
Influenza activity remains low, while RSV activity is very low in most parts of the country.
These levels can change quickly as fall progresses.
National data also do not necessarily reflect conditions in every state or community. Local virus circulation can vary, which is why consumers should consider both national guidance and local conditions.
The current low levels should not be interpreted as evidence that seasonal vaccination is unnecessary.
Vaccination planning generally takes place before respiratory viruses reach their seasonal peaks.
A simple way to compare the three vaccines
The differences become easier to understand when the current recommendations are placed side by side:
| Vaccine | Main current approach | Who is covered? | Typical timing |
|---|---|---|---|
| Flu | Annual vaccination | Everyone 6 months and older, barring contraindications | September or October is preferred |
| COVID | Individual-based decision-making | People 6 months and older, with greater emphasis on risk | Discuss timing based on individual circumstances |
| RSV | Single dose for eligible adults | Everyone 75+ and ages 50-74 with increased risk | August through October is preferred |
The table highlights why there is no single answer for every person.
The flu vaccine has the broadest recommendation. RSV vaccination is limited to specific groups. COVID vaccination requires more individualized consideration.
What older adults should consider this fall
Adults 65 and older should review their seasonal vaccination needs carefully.
Flu vaccination remains important, and people 65 and older have specific influenza vaccine options that can provide stronger immune responses.
COVID vaccination decisions should take age and individual risk into account.
RSV vaccination is recommended for everyone 75 and older. Adults ages 65 through 74 may qualify when they have risk factors for severe RSV illness.
Someone turning 75 may therefore move into a different RSV recommendation category.
That makes age an especially important factor when reviewing vaccination records.
What people ages 50 to 74 should know
Adults between 50 and 74 should pay particular attention to RSV eligibility.
Age alone does not automatically mean every person in this range should receive an RSV vaccine.
The recommendation applies when an individual has an increased risk of severe RSV illness.
People with chronic conditions, weakened immunity, severe obesity or other recognized risk factors may qualify.
COVID and flu recommendations operate differently, so a person should not assume that qualifying for one vaccine automatically means qualifying for another.
The bottom line for fall 2026
The 2026-2027 season brings updated vaccine formulations and clear differences in who should receive each product.
Flu vaccination remains an annual recommendation for people 6 months and older. The new flu vaccine contains three updated components.
The COVID vaccine has been updated for the new season with an XFG-based formulation. Current vaccination decisions use an individual-based approach, with age and risk for severe disease playing major roles.
RSV vaccination remains targeted. Everyone 75 and older should receive a single dose, while adults ages 50 through 74 should receive one when they have an increased risk of severe RSV disease. People who have already received an RSV vaccine generally do not need another dose at this time.
For families, pregnancy and infancy create additional RSV considerations.
The latest guidance also makes it possible for eligible adults to receive several vaccines during the same healthcare visit, although each vaccine has its own eligibility requirements.
Have you reviewed your fall vaccination plans yet? Share your questions or experience in the comments and stay informed as the 2026-2027 season develops.